Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s disease after six months of dosing in a clinical trial, interim data show. “Today’s data once again suggests simufilam could be a transformative, novel therapeutic,” Nadav Friedmann, MD, PhD, chief medical officer at Cassava, said in a press release. “It appears the drug’s unique mechanism of action has potential to provide a treatment benefit following 6 months of…
You must be logged in to read/download the full post.
The post Oral Simufilam Found to Improve Cognition, Behavior After 6 Months’ Use appeared first on BioNewsFeeds.